/

BCT.TO

BRIACELL THERAPEUTICS CORPClosed

5.25−0.06 −1.13%CAD

Toronto · as of Oct 14, 15:44 ET · 15m delay

Open

5.38

Prev close

5.31

Day range

5.255.50

52-week range

3.6820.40

Volume

2.97K0.44×

Mkt cap

45.67M

P/E ttm

—

Fwd P/E

-9.72

EPS ttm

-1.27

Div yield

0.00%

Earnings

—

From 52w high

−74.26%

Price Chart

Yahoo Finance · delayed

BCT.TOOct 14, 2026O 5.38H 5.50L 5.25C 5.25−0.06 (−1.13%)Vol 2.97K

SMA 505.29
SMA 2005.60

1Y change −69.44% since Oct 10, 2025 close540 bars loadedTimes in America/TorontoDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BCT.TO BRIACELL THERAPEUTICS CORP · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.73%
1 month: +5.42%
3 months: −4.89%
6 months: −17.06%
Year to date: −46.43%
1 year: −67.04%

Valuation & ownership

Market cap: 45.67M
Enterprise value: 22.22M
P/E (ttm): —
Forward P/E: -9.72
PEG ratio: —
Price / book: 1.11
Price / sales (ttm): —
EV / EBITDA: -0.70
EPS (ttm): -1.27
EPS (forward): -0.5400
Beta (5y monthly): 1.51
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 8.70M
Float: 7.86M
Short % of float: 0.15%
Short ratio (days): 1.34
Held by insiders: 0.04%
Held by institutions: 6.39%
Avg volume (3m): 6.75K
50-day average: 5.28
200-day average: 5.63
52-week change: −67.04%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 43.4
vs 50-day SMA: −0.67%
vs 200-day SMA: −6.33%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.28%
Realised vol (20d, ann.): 79.7%
From 52-week high: −74.26%
From 52-week low: +42.66%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About BRIACELL THERAPEUTICS CORP

Yahoo Finance profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Sector: Healthcare
Industry: Biotechnology
Headquarters: West Vancouver, BC, Canada
Website: briacell.com
Officers: Dr. William V. Williams FCPA, M.D. CEO, President & Director
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A. CFO & Corporate Secretary
Dr. Miguel A. Lopez-Lago Ph.D. Chief Scientific Officer
Dr. Giuseppe Del Priore M.D., M.P.H.

SEAS

Seasonality · BCT.TO

2012–2026 · monthly returns

Strongest month Mar +11.88%Weakest month Apr −8.36%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-40.0	-11.4	10.4	-0.9	-11.8	-7.8	3.9	3.1	22.7	-13.9			−46.4%
2025	-40.5	-27.9	1.0	16.3	-24.2	-13.8	-74.7	5.8	42.5	0.7	-7.2	-31.1	−91.9%
2024	-27.6	-17.7	-16.6	-23.7	-22.6	-33.4	-32.5	1.5	56.0	-28.8	18.1	-40.9	−89.6%
2023	68.8	-3.2	4.0	-0.5	-19.2	3.2	5.3	10.7	-12.5	-29.8	20.7	9.6	+33.4%
2022	-24.1	19.0	32.7	-29.0	-29.9	16.5	13.9	21.5	-22.9	-5.5	-2.4	-18.5	−44.3%
2021	-8.2	-22.4	13.8	-7.0	-11.1	65.6	-3.3	32.6	21.2	-3.2	27.2	-16.5	+77.3%
2020	104.6	-22.4	-43.3	3.2	-10.5	-38.9	56.6	-24.6	-19.9	-6.1	-11.6	24.8	−50.2%
2019	6.3	23.5	9.5	-30.4	18.8	-15.8	-18.7	-7.7	0.0	-16.7	-20.0	0.0	−50.0%
2018	-12.5	-21.4	18.2	-15.4	9.1	25.0	-10.0	-14.8	13.0	-15.4	-4.5	-23.8	−50.0%
2017	-10.0	30.6	-10.6	-9.5	-2.6	-8.1	-5.9	6.3	-20.6	3.7	-10.7	28.0	−20.0%
2016	-14.3	-28.6	86.7	-28.6	-7.5	-2.7	27.8	-13.0	22.5	-20.4	-20.5	29.0	−18.4%
2015	11.1	-22.5	48.4	32.6	3.3	-23.8	-4.2	2.2	0.0	17.0	-20.0	11.4	+36.1%
2014	20.0	33.3	25.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.5	+121.0%
2013	12.5	-22.2	-14.3	-16.7	40.0	-14.3	0.0	0.0	-16.7	0.0	20.0	-16.7	−37.5%
2012									-8.3	18.2	-30.8	-11.1	−33.3%

INSD

Insider Activity · BCT.TO

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jul 6, 2026	Levin (Gadi)Senior Officer of Issuer	—	28.3K	—
Jul 6, 2026	Lopez-Lago (Miguel A)Senior Officer of Issuer	—	28.3K	—
Jul 6, 2026	Williams (William V)Director of Issuer	—	84.8K	—

BCT.TO

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BCT.TO

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BRIACELL THERAPEUTICS CORP

Seasonality · BCT.TO

Insider Activity · BCT.TO

Congress Trades · BCT.TO

Investors Holding BCT.TO

Investors Holding BCT.TO

Congress Trades · BCT.TO

Insider Activity · BCT.TO

Seasonality · BCT.TO

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About BRIACELL THERAPEUTICS CORP

Earnings & Dividends

News